US FDA Oncology Team Says Sponsor Meetings Are Still Mostly Virtual, And That’s OK

The US FDA’s cancer drug review managers say most sponsors are happy to continue with virtual meetings, even though in-person opportunities are offered. Managers also see advantages to the virtual format for staff development.